Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain

Background: Information on the long-term efficacy of etanercept (ETN) treatment of moderate-to-severe psoriasis according to the Summary of Product Characteristics (SmPC) is scarce. Objectives: We report the efficacy results of an observational clinical trial including 202 patients treated for 12 months with ETN according to SmPC. Methods: Concomitant topical treatment was permitted throughout the study period. Efficacy assessment was done by intention-to-treat analysis with last observation carried forward. Results: Mean % Body Surface Area (BSA) and Psoriasis Area and Severity Index (PAST) decreased from 39.0% and 22.2% at baseline to 7.9% and 4.4%, respectively, at 12 months. Throughout the study duration, PAST 50, PAST 75 and PAST 90 response rates ranged from 72.8% to 95.7%, 55.6% to 84.3%, and 36.1% to 62.2%, respectively. Body mass index and body weight had minor effects on treatment efficacy. Conclusion: ETN treatment according to the SmPC provided sustained improvement of psoriasis throughout one year.